FDA Approves Incyte’s Opzelura as First Vitiligo Therapy
The US Food and Drug Administration has approved Incyte’s Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older.
With this approval, Opzelura is the first and only FDA-approved treatment for repigmentation in patients with vitiligo. It is also the superior topical formulation of a Janus kinase inhibitor approved in the US.
Vitiligo is a chronic autoimmune disease presenting a skin depigmentation caused by the loss of melanocytes, which are pigment-producing cells. Around 1.5 million people are diagnosed with vitiligo in the US....
